Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Within 4 weeks after diagnosis of type 1 diabetes, 10 subjects (pubertal males, 12-17 years
old) will be randomized to either receive multiple daily injection (MDI) using Lantus
insulin, or continuous subcutaneous insulin infusion (CSII; pump therapy). The proposed
protocol compares the changes in diabetes control between pump therapy and MDI treatment
groups. More importantly, however, the study evaluates how these modes of therapy may affect
the honeymoon period and glycemic control, specifically focusing on changes in insulin
sensitivity (measured by the euglycemic-hyperinsulinemic clamp studies and adiponectin
concentration changes) and beta cell function (measured by mixed meal tolerance testing).
Demonstrating that pump therapy at the time of diagnosis of type 1 diabetes prolongs the
honeymoon phase by improving insulin sensitivity and beta cell function may have important
therapeutic implications that could influence the standard of care in pediatric diabetes.